BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Molecular Partners AG Collaborates with Centocor Research And Development, Inc.


1/15/2008 6:45:59 AM

Zurich, Switzerland, January 15, 2008 -- Molecular Partners AG today announced a collaborative research and license agreement with Centocor Research & Development, Inc. The collaboration will focus on the development of DARPins (Designed Ankyrin Repeat Proteins), a novel class of therapeutic proteins to treat inflammatory diseases. Under the collaboration, Molecular Partners will apply its proprietary DARPin technology for the identification of DARPins to two undisclosed targets. Centocor will perform the preclinical and clinical development as well as commercialization of resulting products.

Molecular Partners will receive an upfront payment of $5 million, additional research funding and license fees. Further, Molecular Partners will receive FTE payments for research done under the agreement. Centocor will have exclusive worldwide rights to develop and commercialize products discovered during the research term in exchange for future milestones. In addition, Molecular Partners is entitled to receive royalty payments on net sales of any product from this collaboration. The milestone and royalty payments compare to those of recent agreements in the field. Further details of the agreement have not been disclosed.

“This collaboration with Centocor is an important step to position our DARPin technology as a potential source of innovative drugs”, commented Christian Zahnd, CEO of Molecular Partners. “It also shows the continued execution of our corporate strategy which comprises building a broad portfolio of DARPin-based drugs, from external partnerships as well as from our own internal pipeline.”

“Centocor is a leader in the field of antibody therapeutics and has impressive biopharmaceutical capabilities,” added Patrick Amstutz, CBO of Molecular Partners, “Partners like Centocor will help us maximize the therapeutic potential of DARPins. We are delighted that Centocor has chosen DARPins as an addition to their biopharmaceutical pipeline. The dimension of this deal opens new possibilities for Molecular Partners and positions our company as highly attractive partner for the development of protein therapeutics.”

For further details please contact:

Media relations At Molecular Partners Tony Stephenson Claire Mosley Sue Charles Tel: +44 (0) 20 7457 2020 mp@collegehill.com

Dr. Christian Zahnd, CEO Dr. Patrick Amstutz , CBO Tel: +41 (0) 44 755 77 00 info@molecularpartners.com business@molecularpartners.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES